On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...

DekaBank Deutsche Girozentrale increased its stake in Regeneron Pharmaceuticals by 4.7% this quarter, now holding 221,176 ...

Leerink Partnrs has cut its Q3 2025 earnings estimate for Regeneron Pharmaceuticals, citing lowered expectations across the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Regeneron Pharmaceuticals, Inc.

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

The company had previously selected a $256 million bid from Regeneron Pharmaceuticals as the lead offer. A representative from Regeneron did not immediately respond to a request for comment.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference ...

Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million. The New York-based drugmaker is set to take over 23andMe after winning a ...

Looking at the universe of stocks we cover at Dividend Channel, on 5/20/25, Regeneron Pharmaceuticals, Inc. (Symbol: REGN), PROG Holdings Inc (Symbol: PRG), and Prudential Financial Inc (Symbol ...